LUA006 / Qilu Pharma - LARVOL DELTA

Preclinical development of LUA006: A bispecific EGFR/B7-H3 ADC with dual payloads to address tumor heterogeneity and resistance (AACR 2026) - "LUA006 is a novel bispecific ADC with dual payloads that may enhance efficacy in tumors with heterogeneous expression of a single target or with resistance toward either of dual payloads. Its potent efficacy, reduced toxicity profile and activity in resistant models support further development as a promising therapy for EGFR/B7-H3-expressing solid tumors."

ADC • Bispecific • Heterogeneity • Preclinical • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • CD276 • EGFR